- Home
- SAGE vs BWMX Comparison
SAGE vs BWMX Comparison
Compare SAGE & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- BWMX
- Stock Information
- Founded
- SAGE 2010
- BWMX 1995
- Country
- SAGE United States
- BWMX Mexico
- Employees
- SAGE N/A
- BWMX N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- BWMX Catalog/Specialty Distribution
- Sector
- SAGE Health Care
- BWMX Consumer Discretionary
- Exchange
- SAGE Nasdaq
- BWMX Nasdaq
- Market Cap
- SAGE 413.9M
- BWMX 354.5M
- IPO Year
- SAGE 2014
- BWMX N/A
- Fundamental
- Price
- SAGE $9.30
- BWMX $8.85
- Analyst Decision
- SAGE Hold
- BWMX Strong Buy
- Analyst Count
- SAGE 18
- BWMX 1
- Target Price
- SAGE $10.06
- BWMX $22.50
- AVG Volume (30 Days)
- SAGE 2.4M
- BWMX 77.7K
- Earning Date
- SAGE 07-30-2025
- BWMX 07-24-2025
- Dividend Yield
- SAGE N/A
- BWMX 14.40%
- EPS Growth
- SAGE N/A
- BWMX N/A
- EPS
- SAGE N/A
- BWMX 0.74
- Revenue
- SAGE $47,404,000.00
- BWMX $684,841,453.00
- Revenue This Year
- SAGE $102.21
- BWMX $4.90
- Revenue Next Year
- SAGE $43.01
- BWMX $6.07
- P/E Ratio
- SAGE N/A
- BWMX $11.88
- Revenue Growth
- SAGE N/A
- BWMX 4.87
- 52 Week Low
- SAGE $4.62
- BWMX $7.00
- 52 Week High
- SAGE $13.47
- BWMX $16.04
- Technical
- Relative Strength Index (RSI)
- SAGE 78.92
- BWMX 56.13
- Support Level
- SAGE $6.44
- BWMX $7.85
- Resistance Level
- SAGE $9.33
- BWMX $8.18
- Average True Range (ATR)
- SAGE 0.26
- BWMX 0.36
- MACD
- SAGE 0.33
- BWMX 0.17
- Stochastic Oscillator
- SAGE 98.98
- BWMX 82.86
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.